Delivery Order SPE2DB25D3201-SPE2DB25FNVRL
- Not listed
- The Defense Logistics Agency awarded a $35.5K firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Activase 100 mg vials, with completion scheduled for September 10, 2025. The contract is unclassified as a set-aside and represents a competitively awarded delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $60,767.26 for 100 mg vials of Activase on September 12, 2025, with completion expected by September 15, 2025. This firm fixed-price, non-set-aside contract represents a pediatric delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026. The order will be fulfilled...
- The Defense Logistics Agency awarded a delivery order valued at $5,266.66 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials, with a performance location in Conshohocken, Pennsylvania and an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials valued at $3,351.48. This contract was executed on August 21, 2025, with an ultimate completion date of August 22, 2025, and utilizes firm fixed-price pricing with no set-aside designation. The award was made competitively to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company is headquartered. This...
- The Defense Department's Medical Supply Chain awarded a delivery order valued at $11,730.80 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. The contract, issued on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a firm fixed-price procurement with no set-aside designation. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,676.32 to AmerisourceBergen Drug Corp for the supply of Activase 100 mg vials, with an ultimate completion date of September 12, 2025. This firm fixed-price, non-set-aside contract was awarded competitively on September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $22,365.75 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. This firm fixed price contract, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The award was made through competitive procurement with no set-aside designation. Performance will take place at...
- The Defense Logistics Agency awarded a delivery order valued at $15,172.51 to AmerisourceBergen Drug Corp for the supply of Activase 100 mg vials. This firm fixed-price contract, awarded on September 12, 2025, with an ultimate completion date of September 15, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this order. The delivery order falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $17,019.04 to AmerisourceBergen Drug Corp for 50 mg vials of Activase, a thrombolytic medication used in acute medical emergencies. This firm fixed price contract, awarded on June 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order carries an ultimate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,875.45 to AmerisourceBergen Drug Corp for the supply of Activase 50 mg vials. This firm fixed-price contract, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive, non-set-aside award. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- SPE2DB25D3201Indefinite Delivery Contract
- SPE2DB25D3201-SPE2DB25FNVRLDelivery Order
The Defense Logistics Agency awarded a $20,455.11 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Activase 50 mg vials, with an ultimate completion date of August 15, 2025. This is a firm fixed-price, non-set-aside contract issued to the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor with extensive experience supplying brand-name and generic medications, vaccines, and specialized medical supplies to defense and veteran healthcare systems. The company's selection for this delivery order reflects its capability to meet federal procurement requirements through open competition and its established role supporting the Defense Health Agency and other government healthcare entities through flexible contract mechanisms designed to ensure reliable pharmaceutical supply chains for military operations and personnel.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.5k | 8/14/25 |